TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04502966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dupixent®
Description: An initial dose of 600 mg (two 300 mg injections), followed by 300 mg administered every other week (biweekly), by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grazax®
Description: One Grazax® tablet daily, by sublingual administration.~Grazax® is formulated as a freeze-dried oral lyophilisate/orally disintegrating tablet for oromucosal use. The active pharmaceutical ingredient is a standardized allergen extract derived from extraction and purification of grass pollen from timothy grass (Phleum pratense). The biological activity of the allergen is expressed in Standardized Quality Tablet units (SQ-T) units. The Grazax® dosage is one oral lyophilisate (75,000 Standardized Quality Tablet units (SQ-T) or approximately 2800 Bioequivalent allergy units (BAU), a measure of Phleum pratense SQ total biological potency defined by the FDA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grazax®
Description: One Grazax® tablet daily, by sublingual administration.~Grazax® is formulated as a freeze-dried oral lyophilisate/orally disintegrating tablet for oromucosal use. The active pharmaceutical ingredient is a standardized allergen extract derived from extraction and purification of grass pollen from timothy grass (Phleum pratense). The biological activity of the allergen is expressed in Standardized Quality Tablet units (SQ-T) units. The Grazax® dosage is one oral lyophilisate (75,000 Standardized Quality Tablet units (SQ-T) or approximately 2800 Bioequivalent allergy units (BAU), a measure of Phleum pratense SQ total biological potency defined by the FDA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupixent® Placebo
Description: Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose followed by a single injection administered every other week.~Dupixent® placebo is a subcutaneous injection whose composition is identical to the active Dupixent®, with the exception of the active pharmaceutical ingredient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dupixent® Placebo
Description: Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose followed by a single injection administered every other week.~Dupixent® placebo is a subcutaneous injection whose composition is identical to the active Dupixent®, with the exception of the active pharmaceutical ingredient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grazax® Placebo
Description: One tablet of Placebo (for Grazax®) daily, by sublingual administration.~Grazax® placebo is a tablet whose composition is identical to the active Grazax® tablet with the only exception being exclusion of the active pharmaceutical ingredient, Phleum pratense Standardized Quality Tablet (SQ-T) units.
Study: NCT00782522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eccentric training program
Description: Eccentric training program

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional training program
Description: Traditional training program
Study: NCT02859532

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: elastography SWIRE
Study: NCT03182725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine is prescribed for treatment of chronic heart failure through inhibition of the f-channels (If) within the sinoatrial node.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance that has no therapeutic effect and will act as a control.
Study: NCT02179723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leukosan Adhesive
Description: Leukosan adhesive applied to one wound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leukosan Adhesive
Description: Leukosan adhesive applied to one wound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous suture
Description: Transcutaneous suture applied to one wound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous suture
Description: Transcutaneous suture applied to one wound
Study: NCT02430974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Patients in experimental group will receive oral Icotinib for 4-8months.
Study: NCT02768051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF Ablation
Study: NCT00674869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pit and fissure sealant
Description: pit and fissure sealant on one randomized tooth by pair of permanent molar
Study: NCT04637308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinylated gelatin
Description: Succinylated gelatin (SG, Gelofusine; B. Braun, Crissier, Switzerland) is a clear, inexpensive, safe, colloidal plasma volume-expanding solution, weight-average molecular weight (MWw) 30 kDa.
Study: NCT01648738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa therapy, exercise and educational therapy
Description: During 5 days: Spa therapy (2 hours/day), exercises (30 min/day), educational therapy (45 min/day) including education on physical activities, work, and pain management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Information, counseling, treatment usually provided for sub-acute and chronic low back pain and the back book
Study: NCT04559880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injection [Cyklokapron]
Description: Intra-procedurally, participants will receive 1 gram of intravenous tranexamic acid immediately following the polypectomy. Participants will also take oral tranexamic acid tablets (three times per day) at home for the five days following the procedure.
Study: NCT01535014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dietressa
Description: Comparison of different dosages (frequency) of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dietressa
Description: Comparison of different dosages (frequency) of drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo either (2 tablets 3 times daily) or~(1 tablet 6 times daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo either (2 tablets 3 times daily) or~(1 tablet 6 times daily)
Study: NCT01143038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim will be administered weekly by subcutaneous injection
Study: NCT01108250

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: LOC387715/HTRA1 genotyping
Description: Genomic DNA was extracted from whole blood by standard methods. Genotyping was performed using SNP Genotyping Assays.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LOC387715/HTRA1 genotyping
Description: Genomic DNA was extracted from whole blood by standard methods. Genotyping was performed using SNP Genotyping Assays.
Study: NCT02489513

Intervention type: DRUG
Group type: OTHER
Intervention: [14C]-AG-120
Description: Labeled investigational drug
Study: NCT00862355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC147609
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference147609
Description: IV infusion
Study: NCT03310268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.454% Stannous fluoride (SnF2) and 0.072% sodium fluoride (NaF): 1450 ppm fluoride in total
Description: Participants will be instructed to apply experimental dentifrice (containing 454% SnF2 and 0.072% NaF, 1450 ppm fluoride in total), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1400 ppm fluoride as sodium monofluorophosphate (SMFP)
Description: Participants will be instructed to apply negative control dentifrice (containing 1400 ppm fluoride as SMFP), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stannous Chloride (SnCl2) and 0.15% NaF: 1450 ppm fluoride in total
Description: Participants will be instructed to apply positive control dentifrice (containing SnCl2 and 0.15% NaF, 1450 ppm fluoride in total), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
Study: NCT04265924

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fraction of inspired oxygen (FIO2)
Description: The fraction of inspired oxygen (FIO2) is given accordingly (\>0.85 for the \>0.85 group, and \<0.7 for the \<0.7 group) to the patients during the surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fraction of inspired oxygen (FIO2)
Description: The fraction of inspired oxygen (FIO2) is given accordingly (\>0.85 for the \>0.85 group, and \<0.7 for the \<0.7 group) to the patients during the surgery.
Study: NCT02998736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cialis
Description: Cialis 20 mg daily by mouth for 16 day. 5 days prior to surgery, day of surgery and 10 days post surgery.~Influenza vaccine 0.5mL day of surgery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: One 0.5mL intramuscular injection the day of surgery
Study: NCT04519112

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Catheter Ablation with RMN and MCN

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Description: Catheter Ablation with RMN and MCN
Study: NCT00956514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Neurophysiologic Predictors of Outcome with rTMS Treatment of Major Depressive Disorder
Study: NCT04490733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dual-task walking
Description: Participants will receive 3 times interventions during 10th to 12th course of chemotherapy and 12 weekly phone-call to assess effect and barriers of dual-task walking.
Study: NCT01939054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Study: NCT02397811

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteric Coated Softgels
Description: Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liposomal astaxanthin
Description: Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 3.66 grams per dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Softgel
Description: Standard softgel containing 4 mg astaxanthin per softgel. 3 softgels per dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin Water Soluble Emulsion
Description: Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin Water Dispersible Powder
Description: Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Softgel with Astaxanthin Gel
Description: Standard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 soft gels per dose
Study: NCT02065141

Intervention type: OTHER
Group type: OTHER
Intervention: sip feeding with stable isotope infusion
Description: such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline

Intervention type: OTHER
Group type: OTHER
Intervention: sip feeding with stable isotope infusion
Description: such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline

Intervention type: OTHER
Group type: OTHER
Intervention: sip feeding with stable isotope infusion
Description: such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
Study: NCT04295980

Intervention type: PROCEDURE
Intervention: Surgical removal of the BAVMs
Description: Resection the BAVM nidus by microsurgery.
Study: NCT01637623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 300 mg daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule daily for 6 weeks
Study: NCT01539304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CITUS Dry Syrup
Description: Pranlukast 10% dry syrup, b.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dry syrup, b.i.d
Study: NCT02930356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NSPT
Description: NSPT was done by ultrasonic scalers after administration of pre procedural mouth rinse in the test group (20 smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Scaling and root planing was done by ultrasonic scalers after administration of pre procedural mouth rinse in the control group (20 non smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
Study: NCT02702726

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Congee and juice with coconut gel
Description: 25g coconut oleogel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Congee and juice with coconut oil
Description: 25g coconut oil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Congee and juice with sunflower gel
Description: 25g sunflower oleogel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Congee and juice with sunflower oil
Description: 25g sunflower oil
Study: NCT03260231

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milled seed mix
Description: Dietary intervention with or without seed mix
Study: NCT03092895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Subjects receive Apatinib orally every day with a dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Description: Subjects receive FOLFOX4 treatment every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMOX
Description: Subjects receive GEMOX treatment every 2 weeks
Study: NCT02216643

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Description: Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever Solitaire FR® and/or thromboaspiration with Penumbra System® versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stentriever Solitaire FR® or Penumbra System®
Description: Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever and/or thromboaspiration versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
Study: NCT05847725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic bandaging
Description: The bandages were wrapped circularly along the extremity from the toes to the groin, drawing an 8 at the ankle with a 50% overlap rate, starting with 80% tension and decreasing the pressure proximally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short stretch bandaging
Description: Short tension bandage application was started on postoperative day 1 following the removal of the drains. According to the width of the extremity, using short tension bandages of 6, 8 and 10 cm width, starting from the sole of the foot, the first layer was wrapped circularly with 50% overlapping rate, 80% tension, and wrapped from the sole of the foot to the groin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesio taping was applied in the form of a fan by cutting into 4 longitudinal pieces using the lymphatic correction technique with 15-20% tension, starting from the periphery of the inguinal lymph nodes on the medial, anterior and lateral of the leg, following the removal of the drains from the 1st post-op day.
Study: NCT01244776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acellular corneal matrix
Description: Efficacy of acellular corneal matrix to restore stroma integrity and treat corneal ulcer after lamellar keratoplasty.
Study: NCT01174160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vernakalant hydrochloride
Description: Patients will receive a 3 mg/kg infusion of vernakalant hydrochloride. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of 2 mg/kg vernakalant hydrochloride will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to vernakalent hydrochloride
Description: Patients will receive an infusion of placebo. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of placebo will be administered.
Study: NCT03832634

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fetal Genome Profiling.
Description: Once pregnancy is achieved, patients will undergo non-invasive collection of trophoblast cells (trophoblast retrieval and isolation from the cervix, TRIC) at an early gestational age, approximately 5-6 weeks. The patient will also be screened with blood work for carrier status for genetic conditions.
Study: NCT04146415

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spect scan with mTc99-PYP
Description: . About forty-five minutes after the injection mTc99-PYP , flanner and SPECT-CT mappings will be performed and then the patient will move to the CZT camera and undergo another photograph.
Study: NCT02799953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technology-based self-management model
Description: Participants in the technology-augmented self-monitoring model (intervention group) will use a tablet-based, interactive touch screen self-monitoring system to monitor and manage their chronic conditions. The system is designed to augment patients' abilities to assess, record, and review their health signs while providing text-, audio-, and video-based resources supporting disease self-care.
Study: NCT01274585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation (PTNS)
Description: Stimulation using PTNS device for 30 minutes weekly for 12 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Posterior tibial nerve stimulation
Description: Sham needle placement without active PTNS device for 30 minutes weekly for 12 weeks
Study: NCT01247571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study: NCT02630888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine association in the treatment of young patients with Bipolar I Disorder, partial responders or non-responders to the combination of (quetiapine + lithium) or (quetiapine + aripiprazole) from the ARIQUELI study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to this group will receive a unit dosage identical to that contains 15 mg of memantine during the first week (V0); all have the dose of the placebo (similar to memantine) increased on the second week (V1) in two divided doses of a unit dosage identical to that contains 15 mg of memantine
Study: NCT02723409

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Round Procedure Umbilicoplasty
Description: Umbilicoplasty surgery (belly button reshaping) is performed using the Round Procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scarless round procedure
Description: Umbilicoplasty surgery (belly button reshaping) is performed using the Scarless round procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inverted U Procedure
Description: Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted U Procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inverted VProcedure
Description: Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted V Procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Y deepithelialized Procedure
Description: Umbilicoplasty surgery (belly button reshaping) is performed using the Y deepithelialized procedure